Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes

Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes

Abstract Background Heart failure with preserved ejection fraction (HFpEF) is a common disease with high morbidity and lacks effective treatment. We investigated the protective effects of the long-term application of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin on diabetes-ass...

Full description

Bibliographic Details
Main Authors: Bin Feng, Peiran Yu, Hao Yu, Buyun Qian, Yuan Li, Kangyun Sun, Bimin Shi, Nannan Zhang, Guidong Xu
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Dapagliflozin
Diabetic cardiomyopathy
Heart failure with preserved ejection fraction
AMPK/mTOR
Multi-omic analysis
Online Access:https://doi.org/10.1186/s13098-023-01116-8

Internet

https://doi.org/10.1186/s13098-023-01116-8

Similar Items